Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | PPIA | P62937 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230293 | 0.84 | NPC1 (0.59) | NPC1RAB9APOLBCASP3SMN1; SMN2 | |
| SCHEMBL3105408 | 0.82 | RAB9A (0.60) | NPC1RAB9APOLBCASP3SMN1; SMN2 | |
| SCHEMBL8789037 | 0.82 | HDAC1 (0.62) | NPC1RAB9APOLBCASP3SMN1; SMN2 | |
| SCHEMBL14183610 | 0.81 | SMN1; SMN2 (0.66) | NPC1RAB9APOLBSMN1; SMN2LMNA | |
| SCHEMBL30522295 | 0.80 | NPC1 (0.69) | NPC1RAB9APOLBCASP3SMN1; SMN2 | |
| SCHEMBL18640773 | 0.80 | POLB (0.65) | NPC1RAB9APOLBSMN1; SMN2LMNA | |
| SCHEMBL16193532 | 0.80 | NPC1 (0.69) | NPC1RAB9APOLBCASP3SMN1; SMN2 | |
| SCHEMBL3237870 | 0.80 | NPC1 (0.54) | NPC1RAB9APOLBCASP3SMN1; SMN2 | |
| SCHEMBL4727151 | 0.79 | NPC1 (0.53) | NPC1RAB9APOLBCASP3SMN1; SMN2 | |
| SCHEMBL2566239 | 0.79 | NPC1 (0.47) | NPC1RAB9APOLBCASP3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3965741-B1 | SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR COELIAC DISEASE | DR FALK PHARMA GMBH (DE) | 2023-06-14 | — | — | EP | disclosed |
| EP-3965742-B1 | SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR TG2-RELATED DISEASES | DR FALK PHARMA GMBH (DE) | 2023-06-14 | — | — | EP | disclosed |
| US-20230165845-A1 | SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR TG2-RELATED DISEASES | ZEDIRA GMBH (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230165845-A1 | SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR TG2-RELATED DISEASES | ZEDIRA GMBH (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20220396563-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| EP-3985002-A1 | ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2021214337-A1 | SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR COELIAC DISEASE | DR. FALK PHARMA GMBH (DE) | 2021-10-28 | — | — | WO | disclosed |
| US-20150210671-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210671-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015112847-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | CONFLUENCE LIFE SCIENCES, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20150203535-A1 | DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE | ZEDIRA GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| US-20150203535-A1 | DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE | ZEDIRA GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| EP-2797892-B1 | PYRIDINONE DERIVATIVES AS TISSUE TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-6514997-B2 | Block the activity of picornaviral 3C protease | AGOURON PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1252145-A1 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20010047006-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001040189-A1 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203535-A1 | DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE | PLPBP, PNPO, PDXK | NPC1 4692/4885RAB9A 2849/4885POLB 2106/4885 |
| US-20150210671-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, PDXK, IRAK2 | NPC1 4121/4885RAB9A 4066/4885POLB 2161/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | NPC1 488/4885RAB9A 2087/4885POLB 3304/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | NPC1 488/4885RAB9A 2087/4885POLB 3304/4885 |
| US-20220396563-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | NPC1 488/4885RAB9A 2087/4885POLB 3304/4885 |
| US-20230165845-A1 | SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR TG2-RELATED DISEASES | GLS2, GLS, SULT1E1 | NPC1 2152/4885RAB9A 3689/4885POLB 3383/4885 |
| US-20010047006-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | RNASE1, SERPINB1, RNASEH1 | NPC1 420/4885RAB9A 2911/4885POLB 600/4885 |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | NPC1 488/4885RAB9A 2087/4885POLB 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.